Filing Details

Accession Number:
0001104659-25-027613
Form Type:
13D Filing
Publication Date:
2025-03-24 20:00:00
Filed By:
Advantech Capital L.P.
Company:
Sinovac Biotech Ltd (NASDAQ:SVA)
Filing Date:
2025-03-25
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Advantech Capital L.P. 0 5,851,423 0 5,851,423 5,851,423 8.14%
Advantech Capital Partners Ltd. 0 5,851,423 0 5,851,423 5,851,423 8.14%
Green Vision Partners Limited 0 5,851,423 0 5,851,423 5,851,423 8.14%
Prime Success, L.P. 0 5,851,423 0 5,851,423 5,851,423 8.14%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
Comments to item 13: Based on 71,860,702 Common Shares of the Issuer outstanding as of March 31, 2024 according to the Issuer's annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "2023 Annual Report").


SCHEDULE 13D



Comment for Type of Reporting Person:
Comments to item 13: Based on 71,860,702 Common Shares of the Issuer outstanding as of March 31, 2024 according to the 2023 Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Comments to item 13: Based on 71,860,702 Common Shares of the Issuer outstanding as of March 31, 2024 according to the 2023 Annual Report.


SCHEDULE 13D



Comment for Type of Reporting Person:
Comments to item 13: Based on 71,860,702 Common Shares of the Issuer outstanding as of March 31, 2024 according to the 2023 Annual Report.


SCHEDULE 13D

 
Advantech Capital L.P.
 
Signature:/s/ Yan Yang
Name/Title:Yan Yang / Authorized Signatory
Date:03/25/2025
 
Advantech Capital Partners Ltd.
 
Signature:/s/ Yan Yang
Name/Title:Yan Yang / Authorized Signatory
Date:03/25/2025
 
Green Vision Partners Limited
 
Signature:/s/ Yan Yang
Name/Title:Yan Yang / Director
Date:03/25/2025
 
Prime Success, L.P.
 
Signature:/s/ Yan Yang
Name/Title:Yan Yang / Authorized Signatory
Date:03/25/2025